RecruitingNot ApplicableNCT06336213

Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients

Changes in Antibacterial Therapy Based on Perioperative Dynamics of Presepsin During Reconstructive Thoracic Aorta Surgery


Sponsor

Petrovsky National Research Centre of Surgery

Enrollment

50 participants

Start Date

Jan 23, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria1

  • Thoracic aorta aneurysm/dissection

Exclusion Criteria1

  • Blood sample hemolysis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmpicillin-sulbactam

If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.


Locations(1)

Petrovsky Research National Centre of Surgery (Petrovsky NRCS)

Moscow, Moscow, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06336213


Related Trials